пятница, 22 января 2016 г.

Astellas Pharma $8.50 Tender Offer For Ocata Therapeutics Offer Fails Again

Astellas Pharma $8.50 Tender Offer For Ocata Therapeutics Offer Fails Again


The ongoing battle for control of Ocata Therapeutics inched closer to completion today as an SEC filing reveals that 47% of outstanding shares have been tendered in response to the November 19, 2015 tender offer by Japan based Astellas Pharma to acquire the stem cell therapeutics company. This is the second extended tender deadline that has failed to achieve the required 50.1% shares despite an aggressive campaign by Ocata management to convince shareholders that the $360,000,000 tender offer is in the best interest of shareholders.



from Biotech News